Cargando…

Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (egfr-tkis) and chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung cancer (nsclc) following failure of first-line platinum-based chemotherapy. Although the 3 available therapeutic agents—doc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melosky, B., Agulnik, J., Assi, H.
Formato:	Texto
Lenguaje:	English
Publicado:	Multimed Inc. 2008
Materias:	Medical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2601023/ https://www.ncbi.nlm.nih.gov/pubmed/19079629

Ejemplares similares

Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
por: Melosky, Barbara
Publicado: (2014)

Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
por: Melosky, Barbara
Publicado: (2017)

Editorial: Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
por: Melosky, Barbara
Publicado: (2017)

Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
por: Al-Farsi, Abdulaziz, et al.
Publicado: (2014)

Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice
por: Krainhöfer, Josephine, et al.
Publicado: (2014)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

Maintained Complete Response and Long-Term Survival in Epidermal Growth Factor Receptor Mutated Metastatic Non-Small Cell Lung Cancer with Erlotinib
por: Alkassis, Samer, et al.
Publicado: (2021)

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
por: Melosky, Barbara, et al.
Publicado: (2014)

Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada
por: Perdrizet, Kirstin, et al.
Publicado: (2021)

OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer
por: Wen, Feng, et al.
Publicado: (2018)

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
por: Deng, Wusheng, et al.
Publicado: (2022)

Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer
por: Melosky, B.L.
Publicado: (2008)

Non-small Cell Lung Cancer with Multiple Brain Metastases Treated with Radiosurgery and Erlotinib: A Case Report
por: Sahin, Bilgehan, et al.
Publicado: (2017)

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials
por: Melosky, Barbara
Publicado: (2014)

A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer
por: Esfahani, Khashayar, et al.
Publicado: (2014)

Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
por: Lind, Joline S. W., et al.
Publicado: (2010)

Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment
por: Shi, Sheng-Bin, et al.
Publicado: (2013)

Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer
por: Timmers, Lonneke, et al.
Publicado: (2015)

Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
por: Lee, Dae Ho, et al.
Publicado: (2015)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)

Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice
por: Lai, Eleonora, et al.
Publicado: (2021)

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
por: Reguart, Noemí, et al.
Publicado: (2010)

Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study
por: Wang, Xiangling, et al.
Publicado: (2023)

Low Grade Neuroendocrine Tumors of the Lung
por: Melosky, Barbara
Publicado: (2017)

Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China
por: Wang, Hao, et al.
Publicado: (2022)

Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study
por: Fang, Xiaoxu, et al.
Publicado: (2023)

SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC
por: Yuan, Man, et al.
Publicado: (2019)

Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment
por: Chang, Cheng-Yu, et al.
Publicado: (2023)

Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2021)

A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
por: Pacheco, Jose M., et al.
Publicado: (2019)

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
por: Wong, Matthew K., et al.
Publicado: (2009)

Role of Radiotherapy in Metastatic Non-Small Cell Lung Cancer
por: Faria, Sergio L.
Publicado: (2014)

Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
por: Emery, Ivette F, et al.
Publicado: (2009)

Optimizing the management of advanced non-small-cell lung cancer: a personal view
por: Vincent, M.D.
Publicado: (2009)

Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report
por: Jovanovic, Dragana, et al.
Publicado: (2017)

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
por: Liu, Qiao, et al.
Publicado: (2020)

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
por: He, Yayi, et al.
Publicado: (2016)

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
por: Lu, Shun, et al.
Publicado: (2018)

The Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly: An Evidence-Based Approach
por: Dawe, David E., et al.
Publicado: (2014)

Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients
por: Bisagni, Alessandra, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3ceurct6jnm2ocbptsivapa6k4